{"id":"https://openalex.org/W2004252053","doi":"https://doi.org/10.2217/fon.14.30","title":"Efficacy of Therapy with Bortezomib in Solid Tumors: A Review based on 32 Clinical Trials","display_name":"Efficacy of Therapy with Bortezomib in Solid Tumors: A Review based on 32 Clinical Trials","publication_year":2014,"publication_date":"2014-08-31","ids":{"openalex":"https://openalex.org/W2004252053","doi":"https://doi.org/10.2217/fon.14.30","mag":"2004252053","pmid":"https://pubmed.ncbi.nlm.nih.gov/25303058"},"language":"en","primary_location":{"id":"doi:10.2217/fon.14.30","doi":"https://doi.org/10.2217/fon.14.30","is_oa":false,"landing_page_url":"https://doi.org/10.2217/fon.14.30","pdf_url":null,"source":{"id":"https://openalex.org/S174572715","display_name":"Future Oncology","issn_l":"1479-6694","issn":["1479-6694","1744-8301"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310321119","host_organization_name":"Future Medicine","host_organization_lineage":["https://openalex.org/P4310321119"],"host_organization_lineage_names":["Future Medicine"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Future Oncology","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5090245968","display_name":"Zebo Huang","orcid":"https://orcid.org/0000-0003-2431-3741","observed_orcids":["https://orcid.org/0000-0003-2431-3741","https://orcid.org/0009-0003-4790-5333"]},"institutions":[{"id":"https://openalex.org/I4210152119","display_name":"Jiangsu Province Hospital","ror":"https://ror.org/04py1g812","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210152119"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Zebo Huang","raw_affiliation_strings":["Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing210029, People\u2019s Republic of China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing210029, People\u2019s Republic of China","institution_ids":["https://openalex.org/I4210152119"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026966824","display_name":"Yinxia Wu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I78978612","display_name":"Yangzhou University","ror":"https://ror.org/03tqb8s11","country_code":"CN","type":"education","lineage":["https://openalex.org/I78978612"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yinxia Wu","raw_affiliation_strings":["Department of Oncology, Clinical Medical College of Yangzhou University, No 98 Nantong Western Road, Yangzhou225001, People\u2019s Republic of China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Clinical Medical College of Yangzhou University, No 98 Nantong Western Road, Yangzhou225001, People\u2019s Republic of China","institution_ids":["https://openalex.org/I78978612"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090567341","display_name":"Xin Min ZHOU","orcid":"https://orcid.org/0000-0002-6566-9018","observed_orcids":["https://orcid.org/0000-0002-6566-9018"]},"institutions":[{"id":"https://openalex.org/I4210152119","display_name":"Jiangsu Province Hospital","ror":"https://ror.org/04py1g812","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210152119"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Xin Zhou","raw_affiliation_strings":["Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing210029, People\u2019s Republic of China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing210029, People\u2019s Republic of China","institution_ids":["https://openalex.org/I4210152119"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100757909","display_name":"Jun Xu","orcid":"https://orcid.org/0000-0002-0173-452X","observed_orcids":["https://orcid.org/0000-0002-0173-452X"]},"institutions":[{"id":"https://openalex.org/I4210152119","display_name":"Jiangsu Province Hospital","ror":"https://ror.org/04py1g812","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210152119"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Jun Xu","raw_affiliation_strings":["Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing210029, People\u2019s Republic of China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing210029, People\u2019s Republic of China","institution_ids":["https://openalex.org/I4210152119"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030950854","display_name":"Wei Zhu","orcid":"https://orcid.org/0000-0002-5744-5962","observed_orcids":["https://orcid.org/0000-0002-5744-5962"]},"institutions":[{"id":"https://openalex.org/I4210152119","display_name":"Jiangsu Province Hospital","ror":"https://ror.org/04py1g812","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210152119"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Wei Zhu","raw_affiliation_strings":["Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing210029, People\u2019s Republic of China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing210029, People\u2019s Republic of China","institution_ids":["https://openalex.org/I4210152119"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049678335","display_name":"Yongqian Shu","orcid":"https://orcid.org/0000-0003-0802-1677","observed_orcids":["https://orcid.org/0000-0003-0802-1677"]},"institutions":[{"id":"https://openalex.org/I4210152119","display_name":"Jiangsu Province Hospital","ror":"https://ror.org/04py1g812","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210152119"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yongqian Shu","raw_affiliation_strings":["Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing210029, People\u2019s Republic of China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing210029, People\u2019s Republic of China","institution_ids":["https://openalex.org/I4210152119"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5100442393","display_name":"Ping Liu","orcid":"https://orcid.org/0000-0003-1895-338X","observed_orcids":["https://orcid.org/0000-0003-1895-338X"]},"institutions":[{"id":"https://openalex.org/I4210152119","display_name":"Jiangsu Province Hospital","ror":"https://ror.org/04py1g812","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210152119"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Ping Liu","raw_affiliation_strings":["Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing210029, People\u2019s Republic of China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing210029, People\u2019s Republic of China","institution_ids":["https://openalex.org/I4210152119"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.4497,"has_fulltext":false,"cited_by_count":127,"citation_normalized_percentile":{"value":0.38641243,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":100},"biblio":{"volume":"10","issue":"10","first_page":"1795","last_page":"1807"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11041","display_name":"Ubiquitin and proteasome pathways","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11041","display_name":"Ubiquitin and proteasome pathways","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.002899999963119626,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10620","display_name":"Protease and Inhibitor Mechanisms","score":0.0019000000320374966,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":1.0},{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.9120000004768372},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.9829999804496765},{"id":"https://openalex.org/keywords/ubiquitin-proteasome-system","display_name":"ubiquitin-proteasome system","score":0.9549999833106995},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.8040000200271606},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.7279999852180481},{"id":"https://openalex.org/keywords/monotherapy","display_name":"monotherapy","score":0.6050000190734863},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.7289999723434448}],"concepts":[{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.9809414148330688},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.859343945980072},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.7958701848983765},{"id":"https://openalex.org/C2778367456","wikidata":"https://www.wikidata.org/wiki/Q7251235","display_name":"Proteasome inhibitor","level":3,"score":0.7610703706741333},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.6346905827522278},{"id":"https://openalex.org/C27740335","wikidata":"https://www.wikidata.org/wiki/Q14878333","display_name":"Proteasome","level":2,"score":0.6208005547523499},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5994384288787842},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4760981798171997},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4363569915294647},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.05410212278366089},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000069286","descriptor_name":"Bortezomib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001897","descriptor_name":"Boronic Acids","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D001897","descriptor_name":"Boronic Acids","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001897","descriptor_name":"Boronic Acids","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.2217/fon.14.30","doi":"https://doi.org/10.2217/fon.14.30","is_oa":false,"landing_page_url":"https://doi.org/10.2217/fon.14.30","pdf_url":null,"source":{"id":"https://openalex.org/S174572715","display_name":"Future Oncology","issn_l":"1479-6694","issn":["1479-6694","1744-8301"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310321119","host_organization_name":"Future Medicine","host_organization_lineage":["https://openalex.org/P4310321119"],"host_organization_lineage_names":["Future Medicine"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Future Oncology","raw_type":"journal-article"},{"id":"pmid:25303058","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25303058","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Future oncology (London, England)","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":69,"referenced_works":["https://openalex.org/W1497973518","https://openalex.org/W1654790906","https://openalex.org/W1656816575","https://openalex.org/W1772903887","https://openalex.org/W1966704794","https://openalex.org/W1966740033","https://openalex.org/W1972076184","https://openalex.org/W1973594634","https://openalex.org/W1978729515","https://openalex.org/W1982650056","https://openalex.org/W1992692251","https://openalex.org/W1999353132","https://openalex.org/W2000044224","https://openalex.org/W2009426416","https://openalex.org/W2013660816","https://openalex.org/W2015668100","https://openalex.org/W2019527474","https://openalex.org/W2019835864","https://openalex.org/W2020031294","https://openalex.org/W2024846074","https://openalex.org/W2025839879","https://openalex.org/W2025963365","https://openalex.org/W2032481064","https://openalex.org/W2036211695","https://openalex.org/W2039355568","https://openalex.org/W2048829869","https://openalex.org/W2051670105","https://openalex.org/W2054298919","https://openalex.org/W2056402897","https://openalex.org/W2064663304","https://openalex.org/W2067653691","https://openalex.org/W2068953213","https://openalex.org/W2070730813","https://openalex.org/W2073708080","https://openalex.org/W2074133524","https://openalex.org/W2074610455","https://openalex.org/W2082311266","https://openalex.org/W2091378741","https://openalex.org/W2091394897","https://openalex.org/W2091403769","https://openalex.org/W2093033751","https://openalex.org/W2108235071","https://openalex.org/W2109371953","https://openalex.org/W2111013340","https://openalex.org/W2111217479","https://openalex.org/W2111524632","https://openalex.org/W2111650326","https://openalex.org/W2111810335","https://openalex.org/W2114552883","https://openalex.org/W2115133998","https://openalex.org/W2120590293","https://openalex.org/W2121447624","https://openalex.org/W2124426490","https://openalex.org/W2124560610","https://openalex.org/W2126750639","https://openalex.org/W2127061733","https://openalex.org/W2127688249","https://openalex.org/W2134102124","https://openalex.org/W2136951601","https://openalex.org/W2138077682","https://openalex.org/W2149835016","https://openalex.org/W2154533342","https://openalex.org/W2155468968","https://openalex.org/W2163479859","https://openalex.org/W2164879306","https://openalex.org/W2168405960","https://openalex.org/W2168458127","https://openalex.org/W2169155283","https://openalex.org/W2590052154"],"related_works":["https://openalex.org/W2039374629","https://openalex.org/W2101045201","https://openalex.org/W1966528856","https://openalex.org/W2069791927","https://openalex.org/W2099395323","https://openalex.org/W2103184797","https://openalex.org/W2141253852","https://openalex.org/W2113691575","https://openalex.org/W2409081092","https://openalex.org/W141589247"],"abstract_inverted_index":{"The":[0],"ubiquitin-proteasome":[1],"system":[2],"is":[3,13,144],"a":[4,33,52,100,138],"major":[5],"pathway":[6],"for":[7,20,36],"protein":[8],"degradation,":[9],"so":[10],"that":[11],"proteasome":[12,28,142],"now":[14,30],"considered":[15],"as":[16,32,99],"an":[17],"important":[18],"target":[19],"drug":[21],"discovery.":[22],"Bortezomib,":[23],"the":[24,42,129,135],"first":[25],"US":[26],"FDA-approved":[27],"inhibitor":[29],"used":[31,98],"front-line":[34],"treatment":[35,106],"multiple":[37],"myeloma.":[38],"To":[39],"better":[40,127],"understand":[41,128],"effects":[43,92,131],"of":[44,71,90,132,137,141],"bortezomib":[45,63,96,105,112,133],"in":[46],"cancer":[47],"treatment,":[48],"we":[49],"carried":[50],"out":[51],"review":[53],"based":[54],"on":[55],"32":[56],"published":[57],"clinical":[58,86],"trials":[59],"to":[60,84,126],"determine":[61],"whether":[62],"will":[64],"benefit":[65],"patients":[66],"with":[67,109],"solid":[68],"tumors.":[69],"Information":[70],"complete":[72],"response,":[73,75],"partial":[74],"stable":[76],"disease":[77],"and":[78,134],"objective":[79],"response":[80,117],"rate":[81],"was":[82,93,97,107],"collected":[83],"assess":[85],"outcomes.":[87],"A":[88],"lack":[89],"therapeutic":[91],"observed":[94],"when":[95,104],"single":[101],"agent.":[102],"Meanwhile,":[103],"combined":[108],"other":[110],"agents,":[111],"offered":[113],"no":[114],"statistically":[115],"significant":[116],"versus":[118],"these":[119],"agents":[120],"alone.":[121],"High-quality":[122],"studies":[123],"are":[124],"required":[125],"clinically":[130],"development":[136],"new":[139],"generation":[140],"inhibitors":[143],"absolutely":[145],"necessary.":[146]},"counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":14},{"year":2024,"cited_by_count":10},{"year":2023,"cited_by_count":14},{"year":2022,"cited_by_count":11},{"year":2021,"cited_by_count":16},{"year":2020,"cited_by_count":20},{"year":2019,"cited_by_count":8},{"year":2018,"cited_by_count":13},{"year":2017,"cited_by_count":8},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":2},{"year":2013,"cited_by_count":1}],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2016-06-24T00:00:00"}